- Adults (18-64 years)
- General population
- SARS-CoV-2
- Post-COVID-19
- Non pharmacological intervention
- Rehabilitation
Central Data Repository
Explore the Central Data Repository: Use the filters and keyword search box on the left to find relevant studies. As you refine your search, the map and study list will automatically update to reflect your selections. Selecting a study from the list will provide detailed information about the specific study in question. A full legend can be found here
{content}
Study list
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Fragile population
- Hospital
- Emergency department
- Infectious diseases unit
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Monoclonal antibodies
- Sotrovimab
- Tixagevimab/Cilgavimab
- Casirivimab/Imdevimab
- Bamlanivimab/ Etesevimab
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- SARS-CoV-2
- Post-COVID-19
- General population
- Infants (<1 year)
- Outpatient clinic
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post-COVID-19
- Non pharmacological intervention
- Rehabilitation
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Outpatient clinic
- SARS-CoV-2
- Post-COVID-19
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Outpatient clinic
- SARS-CoV-2
- Post-COVID-19
- Adults (18-64 years)
- General population
- Adolescents (12-17 years)
- Hospital
- Outpatient clinic
- SARS-CoV-2
- Post-COVID-19
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Community
- SARS-CoV-2
- Post-COVID-19
- General population
- Infants (<1 year)
- Adolescents (12-17 years)
- Children (1-11 years)
- Hospital
- SARS-CoV-2
- Post-COVID-19
- Adults (18-64 years)
- General population
- Outpatient clinic
- Primary care
- SARS-CoV-2
- Post-COVID-19
- Adults (18-64 years)
- General population
- Hospital
- Intensive care unit
- SARS-CoV-2
- Post-COVID-19
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Community
- Non-hospital health centre
- Long-term care facility
- Influenza virus
- Influenza A(H5N1) virus
- Influenza A(H7N9) virus
- Avian Influenza
- Pharmacological intervention
- Vaccination
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Outpatient clinic
- SARS-CoV-2
- Post-COVID-19
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antibiotics
- General population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- SARS-CoV-2
- Post-COVID-19
- Adults (18-64 years)
- General population
- Hospital
- Outpatient clinic
- Primary care
- SARS-CoV-2
- Post-COVID-19
- Blood sample
- Stool sample
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- SARS-CoV-2
- Post-COVID-19
- General population
- Infants (<1 year)
- Adolescents (12-17 years)
- Children (1-11 years)
- Hospital
- Outpatient clinic
- Emergency department
- SARS-CoV-2
- Post-COVID-19
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Adolescents (12-17 years)
- Children (1-11 years)
- Hospital
- Outpatient clinic
- Primary care
- SARS-CoV-2
- Post-COVID-19
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Hospital
- Intensive care unit
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Remdesivir
- Immunomodulator
- Steroids
- Baricitinib
- Dexamethasone
- Methylprednisolone
- Infants (<1 year)
- Adolescents (12-17 years)
- Children (1-11 years)
- Hospital
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Remdesivir
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Hospital
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Remdesivir